Clinical trials: Primary Acquired Nasolacrimal Duct Obstruction, open to volunteers
Primary Acquired Nasolacrimal Duct Obstruction
Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study
Primary acquired nasolacrimal duct obstruction (PANDO) is a lacrimal duct obstruction disease characterized by inflammatory fibrosis of the nasolacrimal duct, with primary symptoms including epiphora and increased secretions…
- Trial name
- NCT07154121
- Testing
- 5-fluorouracil group, saline group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Nasolacrimal Duct Obstruction, Epiphora
Outcomes of Stentless Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction.
This prospective, single-arm interventional clinical study aims to evaluate the short- and intermediate-term anatomical, functional, and quality-of-life outcomes of primary stentless endoscopic dacryocystorhinostomy (En-DCR) in…
- Trial name
- NCT07848932
- Testing
- Stentless Endoscopic Dacryocystorhinostomy
- Volunteers
- 40 people
- Sponsor
- Assiut University
Primary Acquired Nasolacrimal Duct Obstruction
Comparative Outcomes of Four Versus Two Balloon Inflation Points in Dacryoplasty for Primary Acquired Nasolacrimal Duct Obstruction
Primary acquired nasolacrimal duct obstruction
- Trial name
- NCT07225244
- Testing
- 2 point balloon dacryoplasty with LacriCATH®, 4 point balloon dacryoplasty with LacriCATH®
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital